Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S, Colombel J, Lukas M, Gisbert J, D'Haens G, Hayee B, Panaccione R, Kim H, Reinisch W, Tyrrell H, Oh Y, Tole S, Chai A, Chamberlain-James K, Tang M, Schreiber S, GARDENIA Study Group. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol 2021; 7:118-127.
17.11.2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
17.11.2021
Lancet Gastroenterol Hepatol 2021; 7:118-127
Danese Silvio, Colombel Jean-Frédéric, Lukas Milan, Gisbert Javier P, D'Haens Geert, Hayee Bu'hussain, Panaccione Remo, Kim Hyun-Soo, Reinisch Walter, Tyrrell Helen, Oh Young S, Tole Swati, Chai Akiko, Chamberlain-James Kirsten, Tang Meina Tao, Schreiber Stefan, GARDENIA Study Group
Weiter
